Stock Track | Bio-Techne Soars in Pre-Market as Q1 Earnings Top Estimates

Stock Track

Oct 30, 2024

Shares of Bio-Techne Corporation (NASDAQ: TECH) surged over 5% in pre-market trading on Tuesday, after the life sciences company reported better-than-expected financial results for the first quarter of fiscal 2025.

For the three months ended September 30, 2024, Bio-Techne posted adjusted earnings per share of $0.42, surpassing analysts' consensus estimate of $0.38. Total revenue rose to $289.5 million, exceeding the forecasted $280.3 million.

The strong performance was driven by robust demand across Bio-Techne's product portfolio, particularly in its core Protein Sciences segment. The company also cited favorable foreign exchange rates as a tailwind.

"Bio-Techne's first quarter results reflect the continued execution of our core strategic priorities," said CEO Chuck Kummeth. "We are well-positioned to capitalize on growing end-market opportunities and remain committed to delivering long-term sustainable growth."

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121980614"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121980614\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121980614?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121980614","market":"hk","top_or_hot":-1,"title":"Stock Track | Bio-Techne Soars in Pre-Market as Q1 Earnings Top Estimates","media":"Stock Track","content":"<p>Shares of Bio-Techne Corporation (NASDAQ: TECH) surged over 5% in pre-market trading on Tuesday, after the life sciences company reported better-than-expected financial results for the first quarter of fiscal 2025.</p>\n\n<p>For the three months ended September 30, 2024, Bio-Techne posted adjusted earnings per share of $0.42, surpassing analysts' consensus estimate of $0.38. Total revenue rose to $289.5 million, exceeding the forecasted $280.3 million.</p>\n\n<p>The strong performance was driven by robust demand across Bio-Techne's product portfolio, particularly in its core Protein Sciences segment. The company also cited favorable foreign exchange rates as a tailwind.</p>\n\n\"Bio-Techne's first quarter results reflect the continued execution of our core strategic priorities,\" said CEO Chuck Kummeth. \"We are well-positioned to capitalize on growing end-market opportunities and remain committed to delivering long-term sustainable growth.\"","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Bio-Techne Soars in Pre-Market as Q1 Earnings Top Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Bio-Techne Soars in Pre-Market as Q1 Earnings Top Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-10-30 18:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Bio-Techne Corporation (NASDAQ: TECH) surged over 5% in pre-market trading on Tuesday, after the life sciences company reported better-than-expected financial results for the first quarter of fiscal 2025.</p>\n\n<p>For the three months ended September 30, 2024, Bio-Techne posted adjusted earnings per share of $0.42, surpassing analysts' consensus estimate of $0.38. Total revenue rose to $289.5 million, exceeding the forecasted $280.3 million.</p>\n\n<p>The strong performance was driven by robust demand across Bio-Techne's product portfolio, particularly in its core Protein Sciences segment. The company also cited favorable foreign exchange rates as a tailwind.</p>\n\n\"Bio-Techne's first quarter results reflect the continued execution of our core strategic priorities,\" said CEO Chuck Kummeth. \"We are well-positioned to capitalize on growing end-market opportunities and remain committed to delivering long-term sustainable growth.\"\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TECH","symbol_name":"Techne Corporation","start_time":0,"source_url":"","article_id":"1121980614","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121980614","pubTimestamp":1730284826,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Bio-Techne Corporation  surged over 5% in pre-market trading on Tuesday, after the life sciences company reported better-than-expected financial results for the first quarter of fiscal 2025.For the three months ended September 30, 2024, Bio-Techne posted adjusted earnings per share of $0.42, surpassing analysts' consensus estimate of $0.38. Total revenue rose to $289.5 million, exceeding the forecasted $280.3 million.The strong performance was driven by robust demand across Bio-Techne'","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TECH":"Techne Corporation"},"translate_title":"股票赛道Bio-Techne盘前飙升，第一季度盈利高于预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TECH":1},"content_text":"Shares of Bio-Techne Corporation (NASDAQ: TECH) surged over 5% in pre-market trading on Tuesday, after the life sciences company reported better-than-expected financial results for the first quarter of fiscal 2025.\nFor the three months ended September 30, 2024, Bio-Techne posted adjusted earnings per share of $0.42, surpassing analysts' consensus estimate of $0.38. Total revenue rose to $289.5 million, exceeding the forecasted $280.3 million.\nThe strong performance was driven by robust demand across Bio-Techne's product portfolio, particularly in its core Protein Sciences segment. The company also cited favorable foreign exchange rates as a tailwind.\n\n\"Bio-Techne's first quarter results reflect the continued execution of our core strategic priorities,\" said CEO Chuck Kummeth. \"We are well-positioned to capitalize on growing end-market opportunities and remain committed to delivering long-term sustainable growth.\"","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}